TNF-alpha blocking agents are very effective in patients with
ankylosing spondylitis (AS), but several cases of liver problems have been published. We systematically studied the frequency of this potential side effect in our AS patients treated with
etanercept. Consecutive AS patients treated with
etanercept for at least 3 months were included.
Liver disease was defined as elevated liver
enzymes more than 1.5 times the upper normal limit (UNL) and was categorised as probably, possibly, probably not or not related to
etanercept treatment. Patients with and without raised liver
enzymes were compared for prognostic factors. A total of 105 patients were included. Fifteen patients had elevated liver
enzymes more than once. In nine cases, the
liver disease was probably (five) or possibly (four) related to
etanercept treatment. The liver
enzyme elevations were serious (>3× UNL) in six cases and resulted in permanent cessation of
etanercept in two cases. The nine patients with
liver disease were compared with patients without elevated liver
enzymes. No differences were found in age or use of alcohol; however, in patients with
liver disease, a higher body mass index and a trend for a higher atherogenic index were observed. Hepatic steatosis was observed in five of six patients with elevated liver
enzymes. Elevated serum
aminotransferases, probably or possibly related to
etanercept treatment, were observed in 9 % of the AS patients. An increased risk for the elevation of liver
enzymes was found in patients with a higher body mass index. We recommend regular testing of liver
enzymes in patients treated with
etanercept.